Showing Results for
- Academic Journals (35)
Search Results
- 35
Academic Journals
- 35
- Search Terms:
- 1From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedRecent gene expression profiling studies have identified five breast cancer subtypes, of which the basal-like subtype is the most aggressive. Basal-like breast cancer poses serious clinical challenges as there are...
- 2From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedAdjuvant endocrine treatment-related adverse effects have a strong impact on patients' quality of life and thereby limit therapy's risk benefit ratio resulting in morbidity and treatment discontinuation. Still, many AI...
- 3From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedThe management of ductal intraepithelial neoplasia (DIN) has substantially changed over the past 30 years, as its incidence has increased (from 2-3% to more than 20%), mainly due to the widespread use of mammography...
- 4From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedBiallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-telangiectasia (A-T). Female relatives of A-T patients have a two-fold higher risk of developing breast cancer (BC) compared with...
- 5From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedMammographic density (MD) adjusted for age and body mass index (BMI) is a strong heritable breast cancer risk factor; however, its biological basis remains elusive. Previous studies assessed MD-associated histology...
- 6From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedThe associations of socioeconomic status (SES) and participation in the breast cancer screening program, as well as consequences for stage of disease and prognosis were studied in the Netherlands, where no financial...
- 7From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedMusic therapy has been used in multiple health care settings to reduce patient pain, anxiety, and stress. However, few available studies have investigated its effect on pain among breast cancer patients after radical...
- 8From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedTrastuzumab (Herceptin[R]) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2. Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clinical benefits of...
- 9From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedTo the Editor, We read with great interest the recent meta-analysis by Zhang et al. [1], which investigated the association between HRAS1 rare alleles and breast cancer risk. This study was very important as it...
- 10From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedThe present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor...
- 11From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedEthnic and racial minority women within the U.S. are less likely to use breast cancer screening (BCS) procedures than non-Latina White women, and are more likely to be diagnosed with cancer at later stages of disease....
- 12From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedEstrogen receptor-[alpha] (ER[alpha]) positive breast cancer frequently responds to inhibitors of ER[alpha] activity, such as tamoxifen, and/or to aromatase inhibitors that block estrogen biosynthesis. However, many...
- 13From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedA previous randomized trial (CALGB 9344/ Intergroup 0148) compared four cycles of adjuvant doxorubicin/cyclophosphamide (AC) to four cycles of AC plus four cycles of paclitaxel (AC + T) and demonstrated that the...
- 14From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedTo the Editor, We read with great interest the two recent meta-analysis of the association between Tumor necrosis factor(TNF)-[alpha] 308G/A polymorphism and breast cancer risk [1,2] and the two related letters [3,...
- 15From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedRare alleles at the HRAS1 variable number of tandem repeats (VNTRs) locus have been implicated in breast cancer risk. Although many studies have showed that rare HRAS1 alleles may be associated with breast cancer risk,...
- 16From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedTrastuzumab (T) is effective in metastatic breast cancer (MBC) with HER2 overexpression and/or amplification, but resistance to T develops in a significant number of HER2-positive patients. Understanding the mechanisms...
- 17From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedSouth Asians from India and Pakistan represent one of the fastest growing immigrant populations in the US, yet there are limited data assessing breast cancers for this distinct ethnic sub-group. The aim of this study...
- 18From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedOverexpression of topoisomerase II protein (topo 2[alpha]) is postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy than human epidermal growth factor receptor type 2...
- 19From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedThus far the clinical benefits seen in breast cancer patients treated with drugs targeting the vascular endothelial growth factor (VEGF) pathway are only modest. Consequently, additional antiangiogenic approaches for...
- 20From: Breast Cancer Research and Treatment. (Vol. 129, Issue 1) Peer-ReviewedThe observed bimodal patterns of breast cancer incidence in the U.S. suggested that breast cancer may be viewed as more than one biological entity. We studied the factors potentially contributing to this phenomenon,...